Hansa Biopharma AB

Halvårsrapporter

Visar 1 grupper

  1. Halvårsrapport Q2 2026

    ENSV
    →

    Financial Performance

    • Revenue for Q1 2026 totaled 34.6 MSEK, compared to 66.3 MSEK in Q1 2025.
    • Product sales accounted for 33.9 MSEK of total revenue.
    • Loss from operations was 142.5 MSEK (Q1 2025: 93.4 MSEK), driven by investments in the U.S.

    Öppna rapport